7月24日，爱德华兹生命科学盘中上涨6.05%，报88.615美元/股。消息面上，公司发布第二季度财报，调整后每股收益0.78美元，超出市场预期的0.74美元，同比增长16.4%；营收17.41亿美元，高于预期的17.00亿美元，同比增长13.7%。核心产品TAVR本季度销售额达12.6亿美元，同比增长11.3%，超出市场预期。公司同时将全年TAVR销售增长预期下限从7%上调至8%。此外，Leerink Partners将公司评级从"与大盘持平"上调至"跑赢大盘"，目标价从87美元提高至101美元，进一步提振市场情绪。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.